CS
TERN

Candriam SCA’s Terns Pharmaceuticals TERN Stock Holding History

Candriam SCA’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$33.3M Sell
631,636
-630,667
-50% -$25.9M 0.17% 131
2025
Q4 		$51M Sell
1,262,303
-1,105,932
-47% -$25.6M 0.25% 90
2025
Q3 		$17.8M Hold
2,368,235
– – 0.09% 194
2025
Q2 		$8.83M Buy
2,368,235
+214,266
+10% +$669K 0.05% 267
2025
Q1 		$5.95M Hold
2,153,969
– – 0.04% 298
2024
Q4 		$11.9M Buy
+2,153,969
New +$14.6M 0.07% 240

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Candriam SCA's TERN Position: Q1 2026 in Review

Candriam SCA reduced its Terns Pharmaceuticals (TERN) stake by 50% in Q1 2026, selling an estimated $25.9M and leaving 631,636 shares worth $33.3M. The position accounts for 0.17% of the portfolio, ranked #131.

Candriam SCA first reported a position in TERN in Q4 2024 and has held it in 6 quarters since. The position peaked at $51M in Q4 2025. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Candriam SCA held 631,636 shares of Terns Pharmaceuticals worth $33.3M as of Q1 2026.
  • Candriam SCA sold 630,667 Terns Pharmaceuticals shares in Q1 2026, an estimated $25.9M.
  • Terns Pharmaceuticals made up 0.17% of Candriam SCA's portfolio in Q1 2026, its #131 holding.
  • Candriam SCA first reported a position in Terns Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • Candriam SCA's Terns Pharmaceuticals position peaked at $51M in Q4 2025.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Candriam SCA's 13F filing for Q1 2026, filed 30 Apr 2026.